Variables | Supplement | Baseline Mean [SD] | End Mean [SD] | P-value$ | Mean Changes (95% CI) | P-value# (time by treatment interaction) |
---|---|---|---|---|---|---|
FBS (mg/dl)* | Cardamom (n = 43) | 93.3 (7.6) | 92.7 (6.7) | 0.5 | −0.6 (−1.0, −0.1) | 0.1 0.2 |
Placebo (n = 44) | 91.5 (7.9) | 92.2 (7.8) | 0.09 | 0.7 (0.1, 1.2) | ||
FBI (μIU/ml) | Cardamom (n = 43) | 8.1 (0.6) | 5.4 (0.9) | < 0.001 | −2.7 (−2.75, −2.64) | < 0.001 < 0.001 |
Placebo (n = 44) | 7.9 (0.9) | 7.5 (1.2) | < 0.001 | − 0.4 (− 0.46, − 0.33) | ||
HOMA-IR | Cardamom (n = 43) | 1.8 (0.1) | 1.2 (0.2) | < 0.001 | −0.6 (− 0.61, − 0.59) | < 0.001 < 0.001 |
Placebo (n = 44) | 1.79 (0.2) | 1.72 (0.3) | 0.001 | −0.07 (− 0.08, − 0.05) | ||
QUICKI^ | Cardamom (n = 43) | 0.347 (0.005) | 0.371 (0.012) | < 0.001 | 0.024 (0.0246, 0.0233) | < 0.001 < 0.001 |
Placebo (n = 44) | 0.350 (0.008) | 0.352 (0.010) | 0.001 | 0.002 (0.0025, 0.0014) | ||
TC (mg/dl) | Cardamom (n = 43) | 204.5 (25.0) | 198.7 (25.2) | 0.01 | −5.8 (−7.4, −4.1) | 0.1 0.2 |
Placebo (n = 44) | 205.0 (26.7) | 204.7 (26.2) | 0.9 | −0.3 (−2.0, 1.4) | ||
TG (mg/dl) | Cardamom (n = 43) | 170.2 (77.4) | 134.5 (54.9) | < 0.001 | −35.7 (−40.1, −31.2) | 0.005 0.01 |
Placebo (n = 44) | 178.0 (74.7) | 168.3 (69.0) | 0.057 | −9.7 (−14.3, − 5.0) | ||
LDL-c (mg/dl) | Cardamom (n = 43) | 125.1 (26.3) | 121.1 (24.2) | 0.01 | −4 (−5.6, −2.3) | 0.01 0.07 |
Placebo (n = 44) | 124.4 (21.7) | 126.3 (23.3) | 0.3 | 1.9 (0.4, 3.3) | ||
HDL-c (mg/dl) | Cardamom (n = 43) | 44.7 (9.7) | 53.1 (10.3) | < 0.001 | 8.4 (7.7, 9.0) | < 0.001 < 0.001 |
Placebo (n = 44) | 45.3 (8.7) | 45.7 (8.4) | 0.4 | 0.4 (−0.1, 0.9) | ||
Irisin (ng/ml)Φ | Cardamom (n = 43) | 25.3(2.9) | 34.4 (4.3) | < 0.001 | 9.1 (8.8, 9.3) | < 0.001 < 0.001 |
Placebo (n = 44) | 25.2 (2.2) | 26.2 (2.8) | < 0.001 | 1.0 (0.8, 1.1) |